1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
LabGenomics Co., Ltd.

LabGenomics Co., Ltd.

KKRX:084650
1,700.00
KRW
+70.00
(+4.29%)
-1,072.66EPS
478.85BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
414.12
529.66
464.38
471.05
486.04
514.1
534.3
1,814.06
3,005.13
2,137.31
1,064.49
1,162.35
1,187.36
1,417.54
Basic EPS, GAAP
30.75
55.25
32.02
14.17
-67.33
-74.17
15.5
649.33
1,244.99
714.5
-70
-322
-867
-1,072.66
Free Cash Flow per Basic Share
-9.73
-6.62
-44.28
-30.02
-105.06
-26.5
20.41
681.07
765.32
452.12
-135.14
-237.37
-433.66
-509.97
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
48.97
- -
- -
- -
- -
Book Value per Share
318.6
429.57
437.04
490.56
433
543.13
493.03
1,200.35
2,366.39
3,079.15
3,068.37
2,913.71
2,015.38
2,009.1
Tangible Book Value per Share
250.96
350.86
314.29
328.94
305.96
464.66
433.6
1,176.02
2,355.3
3,064.22
2,043.88
1,799.81
1,003.42
954.31
Basic Weighted Avg Shares
41
44
51
51
51
54
62
66
67
68
67
74
74
59
Sales/Revenue/Turnover
16,968
23,201
23,590
24,057
24,806
27,539
33,175
119,478
202,407
144,773
71,076
85,898
88,161
84,190
Operating Margin (%)
9.21
11.28
4.38
0.91
-5.73
-7.56
3.26
45.95
51.64
45.73
-9.76
-21.54
-60.7
-61.74
Depreciation Expense
1,387
1,671
2,067
2,282
2,827
3,244
3,803
3,427
3,340
3,965
5,896
9,599
10,311
9,324
Net Income, GAAP
1,260
2,420
1,626
724
-3,437
-3,973
962
42,766
83,855
48,397
-4,674
-23,796
-64,375
-63,708
Effective Tax Rate (%)
- -
0.76
- -
- -
- -
- -
10.5
17.48
23.16
24.4
- -
- -
- -
- -
Profit Margin (%)
7.43
10.43
6.89
3.01
-13.85
-14.43
2.9
35.79
41.43
33.43
-6.58
-27.7
-73.02
-75.67
Working Capital
6,012
10,799
6,354
16,692
14,119
22,720
22,982
62,510
130,248
154,587
95,323
59,252
14,317
10,428
LT Debt
747
143
43
9,366
8,741
6,774
7,379
1,696
4,401
20,195
18,786
2,869
18,056
22,739
Total Equity
13,206
21,236
22,150
25,039
22,348
30,102
30,417
81,640
158,421
210,510
228,143
216,314
149,622
149,156
Return on Invested Capital (%)
- -
12.82
- -
- -
- -
- -
2.46
66.74
57.09
23.74
- -
- -
- -
- -
Return on Capital (%)
- -
12.88
- -
- -
- -
- -
3.27
66.62
66.98
24.93
- -
- -
- -
- -
Return on Common Equity (%)
10.28
14.05
7.5
3.07
-14.5
-15.3
3.21
76.4
70.1
26.37
-2.14
-10.72
-35.18
-35.39

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
35,906
37,443
38,728
LT Borrowings
13,000
13,123
17,263
LT Finance Leases
730
4,933
5,476
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
74
74
Market Capitalization
861,184
672,243
478,848

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
112,298
74,479
71,387
Cash, Cash Equivalents & STI
64,980
58,019
53,871
Accounts Receivable, Net
40,116
11,603
12,693
Inventories
4,084
2,783
2,121
Total Current Liabilities
61,203
60,162
60,959
Payables & Accruals
- -
- -
- -
ST Debt
35,906
37,443
38,728
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.57%
19.86%
-30.83%
Free Cash Flow
341.71%
4.57%
83.56%
Net Income, GAAP
412.83%
104.76%
170.53%
Sales/Revenue/Turnover
31.02%
2.7%
2.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19,897
22,231
21,648
22,101
85,898
2025
21,899
22,301
23,041
20,920
88,161
2026
17,928
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-122.5
0.1
-36
-828.76
-322
2025
-72
-197.34
-46.88
-2,752.45
-867
2026
-63.42
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jae-Hak Ryu
Full Time Employees
142
Sector
Health technology
Industry
Medical specialties
Address
700 Daewangpangyo-ro, Korea Bio Park Bldg. 6F-B, Bundang-gu Seongnam-si GY South Korea 13488
IPO Date
Jul 1, 2013
Website
labgenomics.co.kr
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
LabGenomics Co., Ltd. (084650.KQ) operates as a biotechnology company focused on molecular diagnostics and genetic testing services. The company provides in vitro diagnostic (IVD) products and services, including polymerase chain reaction (PCR)-based diagnostic kits for infectious diseases such as tuberculosis, COVID-19, and respiratory viruses; cancer companion diagnostics; genetic screening tests for prenatal and newborn conditions; and precision medicine solutions like next-generation sequencing (NGS) panels for oncology and hereditary diseases. It also offers contract research organization (CRO) services for bioassay development and validation, along with bioinformatics analysis tools for genomic data interpretation. LabGenomics manufactures and sells branded diagnostic kits under its own labels, such as the Allplex™ multiplex PCR panels for multiplex pathogen detection and the ExoDx™ urine-based prostate cancer test licensed from Bio-Techne; it further provides laboratory testing services through its CLIA-certified facilities. The company serves healthcare providers, hospitals, reference labs, and pharmaceutical firms in the diagnostics and life sciences segments. Founded in 2000 and headquartered in Seoul, South Korea, LabGenomics conducts operations primarily in Asia, with distribution and partnerships extending to North America and Europe. No major partnerships, acquisitions, funding rounds, or strategic shifts have been publicly reported for the company in the last 1-2 years as of late 2025.